In Brief
This article was originally published in The Tan Sheet
Executive Summary
Apsen pays Nestle $215M for infant formula market licenses; UAS Labs acquired in private equity deal; health groups urge Sebelius to follow OTC Plan B order; Abbott continues emerging markets push; more news In Brief.
You may also be interested in...
Supplement Sector Private Equity, M&A Activity Set For 2014 Uptick
Merger and acquisition activity is expected to rise in the supplement sector 2014, says Andre Guardi of consultancy Moss Adams LLC. Companies maturing to ”critical mass” for acquisition, international and big pharma buyers, and interest in ingredient firms are all predicted to drive M&A upward in 2014.
Supplement Sector Private Equity, M&A Activity Set For 2014 Uptick
Merger and acquisition activity is expected to rise in the supplement sector 2014, says Andre Guardi of consultancy Moss Adams LLC. Companies maturing to ”critical mass” for acquisition, international and big pharma buyers, and interest in ingredient firms are all predicted to drive M&A upward in 2014.
Nestle Pays Nearly $12 Bil. For Desirable Pfizer Nutrition Portfolio
Nestle’s $11.85 billion acquisition of Pfizer’s pediatric nutritionals business came in above or at the upper end of most analysts’ expectations. With the deal, Nestle keeps the portfolio – projected to generate $2.4 billion in 2012 sales – away from rivals Danone and Mead Johnson.